These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18298466)

  • 1. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
    Fisher SP; Davidson K; Kulla A; Sugden D
    J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
    Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
    J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
    Imbesi M; Uz T; Manev H
    Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.
    Ochoa-Sanchez R; Comai S; Spadoni G; Bedini A; Tarzia G; Gobbi G
    Neurosci Lett; 2014 Feb; 561():156-61. PubMed ID: 24406151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
    Mini LJ; Wang-Weigand S; Zhang J
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
    Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
    J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramelteon: a review of its therapeutic potential in sleep disorders.
    Pandi-Perumal SR; Srinivasan V; Spence DW; Moscovitch A; Hardeland R; Brown GM; Cardinali DP
    Adv Ther; 2009 Jun; 26(6):613-26. PubMed ID: 19568703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fresh from the pipeline: Ramelteon.
    Buysse D; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
    Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
    Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
    Richardson G; Wang-Weigand S
    Hum Psychopharmacol; 2009 Mar; 24(2):103-11. PubMed ID: 19090503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T; Stubbs C; Walsh JK
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat.
    Fisher SP; Sugden D
    Neurosci Lett; 2009 Jun; 457(2):93-6. PubMed ID: 19429170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.
    Imbesi M; Uz T; Dzitoyeva S; Manev H
    Neurosci Lett; 2008 Jul; 439(1):34-6. PubMed ID: 18501512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramelteon for the treatment of insomnia.
    Borja NL; Daniel KL
    Clin Ther; 2006 Oct; 28(10):1540-55. PubMed ID: 17157111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of ramelteon in a first-night model of transient insomnia.
    Zammit G; Schwartz H; Roth T; Wang-Weigand S; Sainati S; Zhang J
    Sleep Med; 2009 Jan; 10(1):55-9. PubMed ID: 18691937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
    Wang-Weigand S; Watissée M; Roth T
    Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.
    Pandi-Perumal SR; Srinivasan V; Poeggeler B; Hardeland R; Cardinali DP
    Nat Clin Pract Neurol; 2007 Apr; 3(4):221-8. PubMed ID: 17410109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.